Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and highest safe doses of
XL647 in combination with XL147 in adults with solid tumors. XL647 is a small molecule that
potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), and ErbB2. XL147
is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to
inhibit growth and induce apoptosis (programmed cell death) in tumor cells.